UPDATE: Amedisys (AMED) Reports In-Line EPS, Revenue Tops Views; CFO to Retire
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Mizuho Securities Downgrades Amedisys (AMED) Neutral, PT Cut to $55
August 3, 2016 7:06 AM EDTMizuho Securities downgraded Amedisys (NASDAQ: AMED) from Buy to Neutral and cut the price target to $55.00 (from $57.00), following the company's 2Q earnings report. Management pointed out that it had underestimated the HCHB disruption costs previously and is working to correct that. As a... More
